Advancing novel treatments for dry eye and ocular surgery


Kala (NASDAQ: KALA) is a clinical stage pharmaceutical company focused on innovative nanoparticle-based treatments for ocular diseases affecting both the front and back of the eye. Kala leverages its proprietary mucus-penetrating particle (MPP) technology to develop topical ophthalmic formulations with enhanced delivery into ocular tissue by facilitating penetration through the tear film mucus. Beyond ophthalmology, Kala’s MPP technology has potential applications in women’s reproductive health, respiratory and gastrointestinal diseases, and other indications.


Year Invested: 2009
Location: Waltham, Mass.
Visit: www.kalarx.com

Recent News

November 13, 2017
Kala Pharmaceuticals Appoints Todd Bazemore as Chief Operating Officer1

November 7, 2017
Kala Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update

October 25, 2017
Kala Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration For INVELTYS™ (KPI-121 1%)

Read More News

Associated Team Members

Robert Tepper, M.D.
Partner